CytRx slumps further after pricing offering


CytRx (CYTR) prices its 10M share offering at $2.25 per share.

CYTR -18.4% premarket.

From other sites
Comments (2)
  • isha1
    , contributor
    Comments (88) | Send Message
     
    CYTR is like so many other small drug research companies whose main goal is to meet the payroll thru reverse splits and issuing more stocks. My advice to the newbies....stay away!
    9 Oct 2013, 05:26 PM Reply Like
  • WhitneyB
    , contributor
    Comments (890) | Send Message
     
    Over 4 million shares traded today, meaning there were buyers for those shares as well as sellers. The buyers probably liked the Phase 2b 22% ORR for aldoxorubicin, versus 0% for doxorubicin for soft tissue sarcoma. Advancing this rather promising pipeline is the "main goal" of the company, a secondary offering is just one of the means necessary to keep the lights on.
    9 Oct 2013, 06:57 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs